In this discussion hosted by Syngene International's Chief Commercial Officer, Ashu Tandon, joined by:
- Professor Ruth Roberts, Ph.D., ATS, FBTS, ERT, FRSB, FRCPath, Director and Co-founder, ApconiX
- Alan Collis, Ph.D., Vice President, Integrated Drug Discovery Services, Syngene International Ltd.
The key takeaway was that the industry is now considering non-animal methods for toxicology studies, especially in the U.K. and Europe. The move is towards more predictive models like machine learning and organ-on-a-chip to drive safer and more efficient science. Yet another trend being seen is how a CRO's institutional knowledge in GLP tox is being leveraged by big pharma to accelerate their molecules from bench to clinic with ease.
Some other topics discussed included the role of AI today in building an accurate toxicology profile, specific toxicology challenges in emerging modalities like TDP or cell and gene therapy, tips for drug sponsors seeking a toxicology partner, and more.